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Objective: To assess the presence of insulin resistance (IR) in patients with type 1 diabetes (T1DM) according to the
estimated glucose disposal rate formula (eGDR) and the insulin sensitivity score (ISS) and to estimate the correlation
between these two measures and identify the clinical and laboratory markers related to IR.
Research design and methods: Cross-sectional study of adults with T1DM (n = 135). The results of the formulas
that estimate IR were separated into quartiles and correlated with demographic data, clinical characteristics and
laboratory parameters. We analyzed the total and regional adiposity by dual-energy X-ray absorptiometry and skin
fold thickness measurements.
Results: Two thirds of the patients were overweight or obese. A moderate correlation was found between eGDR
and ISS (r = 0.612). The results of both formulas were positively correlated with BMI (r = −0.373 eGDR and r = −0.721
ISS), thoracic-abdominal fat (r = −0.484 eGDR and r = −0.758 ISS), waist/height ratio (r = −0.537 eGDR and r = −0.779
ISS), subscapular skinfold (mm) (r = −0.356 eGDR and r = −0.569 ISS), total dose insulin IU/lean mass (kg) (r = −0.279
eGDR and r = −0.398 ISS), age (years) (r = −0.495 eGDR and r = −0.190 ISS) and diabetes duration (years) (r = −0.428
eGDR and r = −0.187 ISS).
A moderate agreement (Kappa 0.226) was observed between the 1st quartile of results determined by the formulas
in 10.4% of the patients, but the 4th quartile presented a strong correlation (Kappa 0.679). The individuals with IR
that were classified in the 1st quartile by the ISS formula had a higher chance of presenting with acanthosis
nigricans (OR = 5.58, 95% CI =1.46-21.3).
Conclusions: The correlations found in this study indicate the possibility of using clinical and laboratory data to
estimate IR in patients with TDM1. The detection of IR in T1DM patients may allow early intervention and possibly
impact on future diabetes complications.
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Currently, an extensive amount of literature that ex-
plores insulin resistance (IR) and adiposity in popula-
tions of non-diabetic and type 2 diabetic patients
suggests that regional adiposity may be an important
determining factor of IR [1-6]. Few investigations have
explored these associations in type 1 diabetes mellitus
(T1DM). IR is traditionally related to type 2 diabetes* Correspondence: monicamariateixeira@gmail.com
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unless otherwise stated.(T2DM), but its association with T1DM is also well doc-
umented [7-11]. The most probable cause for the lack of
studies in this area is the difficulty of directly evaluating
IR in this population. In individuals at risk for T1DM,
increased IR concomitant to the decrease in beta-cell
mass can alter the balance between insulin sensitivity
(IS) and secretion which then precipitates hyperglycemia
[12]. Thus, this imbalance could result in a more aggres-
sive form of the autoimmune disorder, mediated by im-
munoinflammatory factors common to both processes,
that mediates both IR and the destruction of beta cells,
such as TNF-α and IL-6 [13]. These concepts are part ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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T2DM and chronic hyperglycemia (glucotoxicity) during
the clinical phase of T1DM are associated with decreased
peripheral glucose uptake. Other factors may also influ-
ence IS, such as age, lean body mass, ethnicity, body fat,
weight, physical activity, and drug use [6,8,15-17]. In pa-
tients with T1DM, the development of coronary artery
disease (CAD) occurs decades earlier and with a frequency
tenfold higher than in non-diabetic individuals. Although
the factors associated with increased risk of CAD in this
population are well documented, its pathogenesis remains
unclear [18]. IR is related to diabetic nephropathy and
CAD [19], and the latter represents one of the major
causes of mortality in adult the population with long-
lasting T1DM [7,20,21]. IR is an independent risk factor
for the development of micro and macrovascular diseases
in both T2DM and T1DM patients [7,21].
The hyperinsulinemic-euglycemic clamp technique is
the gold standard for the diagnosis of IR [22]. However,
the difficulty in performing, high cost of and invasive
nature of this procedure limit its large scale use [7,8].
Some clinicians have proposed indirect and simplified
approaches to estimate IR using clinical parameters of
the disease and individual characteristics of the patients
via mathematical formulas [23-26]. In this context, two
formulas that estimate IR have been validated by com-
parison with the hyperinsulinemic-euglycemic clamp
technique and have been used, in spite of some limita-
tions. The first formula associates the estimated glucose
disposal rate (eGDR) with the waist/hip (cm) ratio, his-
tory of systemic arterial hypertension and the haemoglo-
bin A1c (%) level, which are inversely related to IR [23].
The second formula evaluates the insulin sensitivity score
(ISS) based on the waist size (cm), level of glycated
haemoglobin (A1c) (%) and triglycerides (mg/dl) [26].
Therefore, the present study aims to assess the presence
of IR in patients with DM1 with the eGDR and ISS formu-
las, estimate the agreement between these formulas, and
assess the correlation between clinical and laboratory pa-
rameters with IR. This is the first investigation of IR evalu-
ation in a group of Brazilian type 1 diabetic patients using
two mathematical formulas and adiposity markers.
Subjects and methods
This cross-sectional study was performed between January
2011 and June 2012 in Belo Horizonte, Minas Gerais,
Brazil. The study included 135 patients with T1DM se-
lected consecutively and followed up at the outpatient
care department for diabetic patients at the Endocrinology
Service of the Hospital Santa Casa and Hospital das Clíni-
cas of the Universidade Federal de Minas Gerais. T1DM
was diagnosed according to the criteria of the American
Diabetes Association [27]: onset of the disease before 30
years of age and permanent insulinization beginning lessthan one year after the diagnosis [21]. Patients with A1c
values greater than 11.1% (which were the maximum
values used in the two formulas), a pubertal stage less of
than 5, the presence of chronic renal failure, infection or
pregnancy at the time of data collection were not included
in the study. All subjects agreed to participate in the study
and signed an informed consent form. The project was
approved by the Research Ethics Committees of the
institutions involved (Projects CAAE −06121203003-11
and CEP 012/2011).
The anamnesis and physical examinations of the par-
ticipants were conducted by trained examiners. The
following information was obtained from the clinical his-
tory: age, gender, duration of T1DM (years), total insulin
dose IU/ lean mass (kg), arterial hypertension, physical
activity (present in those who performed aerobic activity
or resistance for more than 180 minutes per week) and a
family history of T2DM. The body weight was measured
while patients wore light clothes and no shoes on scales
with an accuracy of 100 g. The height was measured
with the patient barefoot, standing with feet and heels
parallel, and the trunk, shoulders and head touching the
stadiometer (accuracy of 0.5 cm). Waist and hip circum-
ferences were measured in centimeters at the lowest
curvature between the ribs and the iliac crest and at the
area of greatest gluteal protuberance, respectively. The
measurement of the systolic and diastolic blood pressure
(SBP and DBP, mmHg) was performed in supine and
standing positions. Individuals using antihypertensive
medications and/or those with a SBP ≥130 mmHg and/
or DBP ≥80 mmHg were considered hypertensive. The
presence of acanthosis nigricans was recorded during
the physical examination.
Skin fold (SF) thickness was measured at the triceps,
suprailiac and subscapular areas, chest, armpit, abdomen,
and thigh. The following parameters were calculated: body
mass index (BMI) given by weight (kg)/height2 (m), waist/
height ratio (cm), waist-hip ratio (W/H), and fat percent-
age (FP). We used two methods to assess body compos-
ition. The first was a dual-energy X-ray absorptiometry
(DEXA; DEXA Lunar Expert, model 1081) method. Total
body fat mass (kg), free lean bone mass (kg), and percent-
age of body lean mass were calculated by measuring re-
gional arm lean mass (kg), leg lean mass (kg), and trunk
lean mass (kg). The separation between the trunk and legs
and arms was made according to the protocol used by
Shay et al. [23]. One participant was excluded from the
analysis due to a lower limb amputation. From the total of
135 patients, 64 (47.4%) were submitted to DEXA. In the
second method, we measured the SF thickness three times
and used the arithmetic mean of these values. The
adipometer (Lange, Cambridge Scientific Industries, USA)
used has an accuracy of 0.2 mm. To calculate the SF thick-
ness, we used Jackson and Pollock’s formulas [28,29]. For
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thigh) +0.0000016 (thoracic + abdominal + thigh)2 -
0.0002574; and FP = [(4.95/DC) - 4.50] × 100 [28]. For
women SF =1.0994921 - 0.0009929 (triceps + supra-
iliac + thigh) +0.0000023 (triceps + supra-iliac + thigh)2 -
0.0001392; and FP = (5.01/D4.57) × 100 [29].
Blood collections were performed after fasting for a
minimum of 10 hours and abstention from alcoholic
beverages for at least 72 hours. Laboratory tests con-
sisted of the following: fasting plasma glycaemia (FPG),
total cholesterol, HDL cholesterol (HDL), LDL cholesterol
(LDL), triglycerides (enzymatic s3colorimetric method),
A1c (determined by immunoturbidimetry and high per-
formance liquid chromatography (HPLC), both standard-
ized by the National Glycohemoglobin Standardization
Program (NGSP)), glutamic acid decarboxylase (GAD)
antibodies test, and an insulinoma-associated (IA2)
antibodies test (performed by radioimmunoassay and C-
peptide by the chemiluminescence method).
IR was determined using two formulas that were vali-
dated by the hyperinsulinemic-euglycemic clamp technique.
The first formula, eGDR, allows estimates of the glucose re-
lease rate [23] and is calculated based on clinical and la-
boratory parameters according to the following equation:
eGDR =24.4 - (12.97 × W/H) - (3.39 × AH) - (0.60 × A1c);
where W/H is the value of the waist/hip ratio and AH indi-
cates the presence of arterial hypertension (yes = 1, no = 0).
The second formula estimates the ISS [26] and is calculated
with the equation: LogeIS = 4.64725 - 0.02032 (W, cm) -
0.0977 (A1c, %) - 0.00235 (TG, mg/dl); where Loge IS is
the logarithm of IS, W is the waist size, and TG is the
triglyceride level.
The results of the eGDR and ISS formulas were
separated into quartiles as follows: eGDR 1st quartile
(≤6.61), 2nd quartile (6.62 to 8.76), 3rd quartile (8.77 to
10.33), and 4th quartile (>10.33); and ISS 1st quartile
(≤6.22), 2nd quartile (6.23 to 8.16), 3rd quartile (8.17 to
9.56), and 4th quartile (>9.56).
Sample size was calculated according to the following
parameters: 0.25 prevalence of metabolic syndrome (and
hence, IR) in T1DM patients [10,30], 0.12 estimation
error, 5% alpha and 20% power. The estimated sample
size was 120 patients for an error tolerance of 0.05. These
patients were randomly selected by simple randomization
from a pool of 350 DM1 patients that attended the institu-
tions where the research was performed.
Statistical analyses were performed using the computer
software IBM SPSS, version 20.0 (SPSS Inc., Chicago, IL,
USA) and R version 3.01 (2013-05-16, Vienna, Austria).
We used histograms and Shapiro-Wilk tests to verify the
normality of continuous data. The Student’s T tests and
Mann–Whitney U tests were used to compare means
and medians of continuous variables, and the Person’s
chi-square test or Fisher’s exact test to compare categoricalvariables between the men and women. Spearman’s correl-
ation coefficient was used to evaluate the correlation be-
tween the IR formulas and markers of adiposity, clinical
findings, laboratory parameters and T2DM family history.
The original data from the formulas was calculated and di-
vided into quartiles because the formulas do not have cut-
off values for comparative analyses. We divided patients
into three groups (1st quartile, 2nd + 3rd quartiles and 4th
quartile). The Jonckheere-Terpstra test was used to com-
pare medians of continuous variables (without Gaussian
normal distribution) between the three groups (1st quar-
tile, 2nd + 3rd quartiles and 4th quartile) and Chi-square
test for trends and Fisher’s exact test to compare categor-
ical variables between the three groups (1st quartile, 2nd +
3rd quartiles and 4th quartile). All analyses were performed
using p < 0.05 as a statistically significant level. The two
formulas in question were compared using the Kappa coef-
ficient. Finally, the association between the 1st quartile of
the ISS formula data and the occurrence acanthosis nigri-
cans was analyzed using the odds ratio.
Results
The characteristics of the 135 subjects with T1DM are
presented in Table 1, which shows the clinical and labora-
tory profiles according to gender. The proportion of
smokers was higher among men (20.4% vs. 8.2% p =
0.029). A total of 46.6% of men and 33.8% of women were
classified as overweight (BMI ≥25 kg/m2). In the study
population, 71.5% of patients had a positive family history
of T2DM. The auto antibodies anti-GAD and anti-IA2
were positive in 87.3% and 25% of women and 92.1% and
16.7% of men, respectively. C-peptide levels were un-
detectable in 88.1% of women and 88.9% of men.
Table 2 shows the correlation analysis between the ISS
and eGDR formulas by gender and fat markers, clinical
and laboratory parameters, T2DM family history and
physical activity. According to the Spearman’s rank cor-
relation coefficient, a moderate positive correlation was
found between the values of the two formulas (r = 0.612,
p < 0.001) (Figure 1).
The clinical and laboratory characteristics of diabetic
patients belonging to the 1st and 4th quartiles according
to the eGDR and ISS formulas are presented in detail in
Tables 3 and 4. The variables that were significantly dif-
ferent between the 1st quartile and 4th quartile of the
eGDR formula data comprise age, duration of diabetes,
BMI, thoracic-abdominal fat (absolute and percentage),
total dose insulin IU/lean mass (kg), arm fat, waist/
height ratio and scapular skinfold. The variables that
were significantly different between the 1st quartile and
4th quartile of the ISS formula data comprise age, dur-
ation of diabetes, BMI, total insulin dose per lean mass,
total fat percentage, arm fat, leg fat, thoracoabdominal
fat (absolute and percentage), scapular skinfold, triceps
Table 1 Clinical and laboratory profile of type 1 diabetic patients
Variables Male Female P value
N =135 58 (43%) 77 (57%)
Age (years) 30 (17–68) 27 (12–58) 0.139
TDM1 duration (years) 15.5 (1–48) 15.0 (1–49) 0.556
eGDR 8.49 (1.26-11.82) 9.3 (2.35-12.6) 0.055
ISS 7.60 (±2.34) 8.30 (±2.28) 0.090
BMI† (kg/m2) 24.0 (19.0-36.0) 24.0 (17.0-46.0) 0.255
Waist (cm) 84.5 (65–119) 78.0 (64–123) 0.001
Hips (cm) 98.0 (80–120) 96.0 (90–150) 0.938
Waist/height ratio 49.3(36.1-70.4) 48.1 (38.5-78.9) 0.81
Waist/hip ratio 0.85 (0.75-1.12) 0.79 (0.67-1.48) <0.001
Total insulin dose UI/Lean mass (kg)‡ 0.98 (0.32-3.15) 1.14 (0.19-3.35) 0.085
Total lean mass (kg)‡ 53.15 (±9.55) 36.82 (41.63) <0.001
Thoracic-abdominal fat (kg)‡ 3.63 (1.0-28.65) 6.65 (2.34-17.37) 0.053
Leg fat (kg)‡ 3.86 (0.85-12.93) 6.81 (2.3-16.34) <0.001
Arm fat (kg)‡ 0.738 (0.182-3.743) 1.81 (0.51-6.78) <0.001
Total lean mass percent‡ 83.8 (56–95) 68.7 (50–86) <0.001
Total Fat Percent‡ 16.24 (5.3-43.6) 33.00 (14.4-50) <0.001
Thoracic-abdominal total percent‡ 14.76 (5–68.4) 26.30 (11–50.3) 0.004
Leg fat percent‡ 18.90 (8.7) 39.27 (8.33) <0.001
Arm fat percent‡ 11.1 (4.1-32.6) 38.0 (14.9-59.1) <0.001
Triceps skinfold (mm) 12.30 (4.33-31.67) 20.67 (8.33-48.67) <0.001
Scapular skinfold (mm) 15.70 (6.33-41.67) 18.33 (6.33-39.0) 0.035
Total cholesterol (mg/dL) 160 (76–282) 169 (85–332) 0.043
HDL cholesterol (mg/dL) 50 (27–81) 58 (36–124) 0.001
LDL cholesterol (mg/dL) 94.0 (35–178) 98.0 (20–252) 0.419
Triglycerides (mg/dL) 62.5 (26–310) 63 (25–295) 0.697
Systolic arterial pressure mmHg 120 (90–200) 120 (90–160) 0.012
Diastolic arterial pressure mmHg 80 (50–120) 80 (50–100) 0.017
A1c (%) 7.6 (5.4-11) 7.9 (5.8-11.1) 0.328
HbA1c(mmol/mol) 60 (36–94) 63 (40–98) 0.328
Total insulin dose (IU/kg) 55 (12–340) 44 (8–122) 0.036
Physical activity – yes 41 (70.7%) 43 (56.6%) 0.107
Acanthosis – yes* 4 (7.3%) 6 (8.2%) 0.10
Family history of TDM2 – yes 40 (70.2%) 53 (72.6%) 0.845
P value: Person’s chi- square, Fisher’s exact test*, Student’s T test, and the Mann–Whitney test for differences between, frequencies, frequencies, means and medians.
†Body mass index = weight (kg)/height (m)2.
‡Patients who underwent densitometry for analysis of body composition (n = 64).
eGDR estimated glucose disposal rate, ISS insulin sensitivity score, BMI body mass index, A1c glycated haemoglobin.
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centage of total fat, and hip and waist/height ratio. A
moderate positive association was found between the
first and 4th ISS quartiles regarding HDL values and the
presence of acanthosis nigricans.
The variables that were strongly concurrent between
the 1st and 4th quartiles for both formulas comprise
BMI, waist/height ratio, subscapular skinfold, total doseinsulin IU/lean mass(kg), age, diabetes duration and
thoracoabdominal fat (absolute and percentage).
In the studied population, 14 (10.4%) patients pre-
sented results calculated by both formulas that corre-
sponded with the 1st quartile, suggesting IR, and 63
(85.7%) patients were overweight or obese. The agree-
ment between the 1st quartiles of the eGDR and ISS for-
mulas was slight-to-moderate (Kappa = 0.226), and the
Table 2 Spearman linear correlation between eGDR, ISS and clinical and laboratory profiles by gender
Variables eGDR ISS
SLC General SLC General
SLC Male SLC Female SLC Male SLC Female
Total lean mass (kg)§ −0.121 (0.335) −0.262 (0.034)
0.064 (0.751) −0.103 (0.533) −0.443 (0.021) −0.262 (0.107)
Thoracoabdominal fat (kg)§ −0.484 (<0.001) −0.758 (<0.001)
−0.560 (0.002) −0.478 (0.003) −0.825 (<0.001) −0.743 (<0.001)
Leg fat (kg)§ −0.068 (0.592) −0.351 (0.004)
−0.296 (0.134) −0.078 (0.648) −0.563 (0.002) −0.374 (0.23)
Arm fat (kg)§ −0.381 (0.002) −0.592 (<0.001)
−0.497 (0.08) −0.390 (0.17) −0.667 (0.001) −0.662 (<0.001)
Percentage of total lean mass§ 0.262 (0.036) 0.436 (<0.001)
0.464 (0.015) 0.322 (0.052) 0.659 (0.001) 0.534 (<0.001)
Percent total Fat§ −0.268 (0.032) −0.476 (<0.001)
−0.464 (0.015) −0.349 (0.034) −0.659 (0.001) −0.640 (<0.001)
Percentage of thoracoabdominal fat§ −0.359 (0.004) −0.574 (<0.001)
−0.369 (0.058) −0.464 (0.004) −0.592 (0.001) −0.731 (<0.001)
Percent fat leg§ −0.024 (0.848) −0.167 (0.188)
−0.311 (0.114) −0.067 (0.695) −0.487 (0.01) −0.260 (0.120)
Percent arm fat§ −0.224 (0.75) −0.402 (<0.001)
−0.545 (0.003) −0.326 (0.049) −0.718 (<0.001) −0.619 (<0.001)
Triceps skinfold (mm) −0.62 (0.518) −0.336 (<0.001)
−0.286 (0.44) −0.906(0.457) −0.595 (<0.001) −0.380 (0.002)
Subscapular skinfold (mm) −0.356 (<0.001) −0.569 (<0.001)
−0.485 (0.001) −0.374 (0.003) −0.676 (<0.001) −0.594(<0.001)
HDL cholesterol (mg/dL) 0.122 (0.158) 0.231 (0.007)
0.076 (0.570) 0.079(0.496) 0.197 (0.138) 0.185 (0.108)
Total cholesterol (mg/dL) −0.035 (0.69) −0.140 (0.107)
0.152 (0.259) −0.022(0.846) −0.205 (0.125) −0.147 (0.201)
BMI||† (kg/m2) −0.373 (<0.001) −0.721 (<0.001)
Waist/height ratio|| −0.537 (<0.001) −0.779 (<0.001)
Age (years)|| −0.495 (<0.001) −0.190 (0.027)
Diabetes duration (years)|| −0.428 (<0.001) −0.187 (0.03)
Total dose insulin IU/Lean mass(kg)§|| −0.279 (0.0023) −0.398 (<0.001)
Acanthosis nigricans - yes|| −0.110 (0.218) −0.258 (0.003)
LDL cholesterol (mg/dL)|| −0.115 (0.187) −0.154 (0.075)
Family history of TDM 2|| - yes 0.15 (0.868) −0.096 (0.277)
Physical activity – yes|| 0.142 (0.102) 0.024 (0.78)
P value: Spearman correlation.
†Body mass index = weight (kg)/ height (m)2.
§Patients who underwent bone densitometry for body composition analysis (n = 64).
||Variables where there was no significant difference for the gender factor. See Table 1.
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was strong (Kappa = 0.679). The individuals with IR
classified in the 1st quartile by the ISS formula had a
higher chance of presenting with acanthosis nigricans
(OR = 5.58, 95% CI = 1.46-21.3).Discussion
According to the classic definition of T1DM, individuals
with a total deficiency of insulin are characterized as
T1DM patients. During the last two decades there has
been an increase in the overweight population of type 1
Figure 1 Scatter plot of the correlation values between the first
quartile and fourth quartile of data from the formulas that
estimate the glucose disposal rate (eGDR) and the insulin
sensitivity score (ISS) and the Spearman correlation coefficient.
Table 3 Clinical and laboratory characteristics of type 1 diabe
Variables eGDR 1st quartile eG
Patients n = 33 (24.4%)
Gender (Male) 18 (54.5%)
Age (years) 37 (20–68)
Duration of diabetes (years) 21 (2–48)
BMI† (kg/m2) 25 (19–35)
Waist/height ratio 52.6 (40.5-70.4)
Total insulin dose IU/Lean mass (kg)§ 1.13 (0.46-3.15)
Total lean mass (kg)§ 40 (32.9-64.2)
Thoracoabdominal fat (kg)§ 9.38 (2.3-28.7)
Leg fat (kg)§ 5.40 (0.9-11.0)
Arm fat (kg)§ 1.98 (0.3-6.8)
Total lean mass percentage§ 0.70 (0.5-0.9)
Total fat percentage§ 0.29 (0.07-0.5)
Thoracoabdominal fat percentage§ 0.29 (0.09-0.54)
Leg fat percentage§ 0.31 (0.06–0.50)
Arm fat percentage§ 0.32 (0.55-0.59)
Triceps skinfold (mm) 15.5 (6.6-30.0)
Scapular skinfold (mm) 19.5 (7.7-39.0)
Acanthosis (yes)* 2 (6.5%)
Physical activity (yes) 17 (53.1%)
Family history of DM2 (yes) 24 (72.7%)
Total insulin dose (IU/day) 48 (20–340)
Total Cholesterol (mg/dl) 166 (104–322)
HDL (mg/dl) 56 (27–87)
LDL (mg/dl) 100 (57–252)
P-value: Jonckheere-Terpstra test, Chi-square for trends, Fisher Exact Test* for comp
†Body mass index = weight (kg)/height (m)2.
§Patients who underwent densitometry for the analysis of body composition (n = 64
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tients has tripled from the 1980s to the 1990s [31], fol-
lowing the trend of the general population [16]. In our
study population, 46.6% of men and 33.8% of women
were classified as overweight (BMI ≥25 kg/m2). Among
the patients who underwent DEXA, we found an in-
creased percentage of total body fat in both men and
women, specifically in the groups classified into the 1st
quartile by the formulas. In this group, the percentage of
total and thoracoabdominal fat, subscapular skinfold
(SF), and the waist/height ratio, which are markers of
visceral fat, were increased significantly compared to the
other quartiles of both formulas. Forty-four percent
of young Hispanic Americans with T1DM from the
SEARCH study were overweight or obese [32], suggest-
ing a new phenotype in a group of patients that were
considered lean until that time. These results also con-
firmed previous observations in T1DM patients showing
that fat stored in the abdomen is associated with antic patients compared by eGDR quartiles
DR 2nd and 3rd quartiles eGDR 4th quartile P value
n = 69 (51.1%) n = 33 (24.4%)
29 (42.0%) 11 (33.3%) 0.083
29 (12–58) 23 (12–55) < 0.001
14 (1–49) 10 (0–27) < 0.001
24 (17–46) 21 (18–28) 0.001
50 (38.7-78.8) 44.2 (36.1-52.2) < 0.001
1.14 (0.52-3.35) 0.91 (0.19-1.63) 0.059
41 (30.1-81.1) 38.5 (30.1-58.0) 0.656
6.34 (1.0-20.1) 4.71 (1.7-12.5) 0.002
6.29 (0.9-12.9) 5.89 (1.8-16.3) 0.901
1.46 (0.2-3.7) 1.03 (0.3-4.8) 0.017
0.72 (0.6-1.0) 0.78 (0.5-0.9) 0.108
0.28 (0.05-0.40) 0.21 (0.08-0.49) 0.103
0.25 (0.05-0.41) 0.19 (0.08-0.68) 0.02
0.31 (0.06-0.48) 0.30 (0.11-0.60) 0.852
0.30 (0.4-0.43) 0.26 (0.45-0.56) 0.122
17.8 (4.3-48.7) 19.0 (5.3-28.7) 0.730
17.3 (6.3-41.7) 13.8 (6.3-26.0) 0.001
7 (10.8%) 1 (3.1%) 0.432
43 (62.3%) 24 (72.7%) 0.103
43 (66.2%) 26 (81.3%) 0.457
52.5 (17–161) 36 (8–85) 0.041
166 (85–240) 165 (76–250) 0.853
52 (32–124) 58 (32–107) 0.474
96 (20–178) 93 (35–150) 0.357
arisons of medians, frequencies and frequencies.
).
Table 4 Clinical and laboratory characteristics of type 1 diabetic patients compared by ISS quartiles
Variables ISS 1st quartile ISS 2nd and 3rd quartiles ISS4th quartile P value
Patients n = 34 (25.2%) n = 68 (50.4%) n = 33 (24.4%)
Gender (Male) 18 (52.9%) 30 (44.1%) 10 (30.3%) 0.063
Age (years) 32 (15–68) 27 (12–62) 25 (15–55) 0.016
Duration of diabetes (years) 17 (1–49) 16 (2–43) 10 (0–27) 0.020
BMI (kg/m2)† 27.5 (19–46) 24 (17–30) 21 (18–26) < 0.001
Waist/height ratio (cm) 56.8 (40.5-78.8) 49.0 (38.7-61.9) 43.7 (36.1-51.7) < 0.001
Total insulin dose IU/Lean Mass (kg)§ 1.43 (0.53-3.35) 1.05 (0.46-1.77) 0.92 (0.19-1.63) 0.002
Total lean mass (kg)§ 0.63 (0.5-0.9) 0.74 (0.5-1.0) 0.79 (0.7-0.9) 0.001
Thoracoabdominal fat (kg)§ 13.13 (7.2-28.7) 6.28 (1.0-13.6) 3.4 (1.5-6.9) < 0.001
Leg fat (kg)§ 7.10 (3.6-12.9) 5.45 (0.9-16.3) 4.76 (1.8-10.4) 0.011
Arm fat (kg)§ 2.65 (1.2-6.8) 1.36 (0.2-4.9) 0.816 (0.2-2.2) 0.001
Total lean mass percentage§ 0.63 (0.5-0.9) 0.74 (0.5-1.0) 0.79 (0.7-0.9) 0.001
Total fat percentage§ 0.37 (0.18-0.50) 0.25 (0.05-0.49) 0.20 (0.08-0.34) < 0.001
Thoracoabdominal fat percentage§ 0.33 (0.22-0.50) 0.21 (0.05-0.41) 0.16 (0.06-0.68) < 0.001
Leg fat percentage§ 0.35 (0.14-0.48) 0.33 (0.06-0.60) 0.29 (0.11-0.49) 0.237
Arm fat percentage§ 0.39 (0.16-0.59) 0.28 (0.04-0.56) 0.18 (0.04-0.41) 0.001
Triceps skinfold (mm) 21.7 (9.7-26.6) 15.7 (4.3-30.0) 15.0 (5.3-25.7) 0.003
Scapular skinfold (mm) 24.3 (14.7-41.7) 16.0 (6.3-36.0) 12.0 (6.3-23.7) < 0.001
Acanthosis (yes)* 6 (19.4%) 3 (4.6%) 1 (3.1%) 0.013
Physical activity (yes) 19 (57.6%) 43 (63.2%) 22 (66.7%) 0.447
Family history of DM2 (yes) 25 (78.1%) 44 (66.7%) 24 (75%) 0.783
Total insulin dose (IU/day) 60 (34–340) 46 (17–111) 36 (8–85) < 0.001
Total cholesterol (mg/dL) 169 (117–282) 167 (76–332) 162 (76–250) 0.268
HDL (mg/dL) 46 (27–87) 57 (35–107) 56 (32–124) 0.004
LDL (mg/dL) 99 (49–178) 96 (20–252) 88 (35–150) 0.127
P-value: Jonckheere-Terpstra test, Chi-square for trends, Fisher Exact Test* for comparisons of medians, frequencies and frequencies.
†Body mass index = weight (kg)/height (m)2.
§Patients who underwent densitometry for the analysis of body composition (n = 64).
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http://www.dmsjournal.com/content/6/1/131increased risk of cardiovascular disease. Our data are in
agreement with the results of a study by Shay et al. [24]
that showed associations between total and regional adi-
posity, determined by DEXA. The negative association
between insulin sensitivity in T1DM and regional and
overall adiposity measures improved the prediction of
the eGDR and ISS equations for identifying individuals
with T1DM at risk for IR. This further supports the rela-
tionship established between general obesity and IR in
the studied population. The phenotypical change in the
individuals with T1DM is most likely related to the aug-
mentation of the use of insulin, irregular food habits,
long time periods spent in sedentary activities, insufficient
physical activities and, primarily, genetic backgrounds.
The eGDR and ISS formulas were associated with the
following general clinical features: BMI, thoracoabdom-
inal fat, subscapular SF and waist/height ratio. The
results of many studies show that IR is related to waist
circumference, which, despite limitations, is a usefulclinical marker of abdominal adiposity. The association
of the formulas with visceral fat deposits was strong in
our study. Uncertainty still exists regarding the best way
to measure adiposity and evaluate metabolic risks in
T1DM patients. DEXA is quickly becoming the pre-
ferred technique to evaluate body fat distribution, but
the high accuracy provided by this method is associated
with increased operational costs. Although DEXA is
clinically useful to quantify regional adiposity, current
studies suggest that this method is not necessary for the
estimation of IR in the general population of individuals
with T1DM [24]. More useful clinical markers of obesity,
such as BMI, and abdominal adiposity, such as waist and
waist/height ratio, have exhibited strong associations
with IR. Our results support the regular use of these
simple and inexpensive measures to evaluate the risk of
IR in T1DM patients.
Our results provide evidence for an association be-
tween the formulas used to determine IR and insulin
Teixeira et al. Diabetology & Metabolic Syndrome 2014, 6:131 Page 8 of 10
http://www.dmsjournal.com/content/6/1/131dose per lean body mass in type 1 diabetic patients.
Available evidence suggests that the insulin dose by lean
mass and by body surface may be associated with IR
[33]. Similar to the increased values of obesity and trigly-
ceride markers, the presence of arterial hypertension,
low HDL levels and acanthosis nigricans are related to
central adiposity and IR [34]. In the group of patients
analyzed using the IR formulas, in addition to the posi-
tive associations regarding the previously mentioned var-
iables, a strong negative correlation between the amount
of thoracoabdominal fat and the ISS value (r = −0.758
p < .001) was observed, which provides further evidence
that an increased amount of fat stored in the abdomen
could be a risk factor for the development of IR. Fur-
thermore, ISS was also significantly associated with
acanthosis nigricans (a clinical marker of IR), triceps SF,
percentage of total fat, percentage of lean mass, and
HDL suggesting its enhanced usefulness in the classifica-
tion of IR patients. This most likely occurs because the
ISS formula includes the triglyceride level, which is an
important factor associated with of IR. We found associ-
ations between age and duration of diabetes in years
with IR in both formulas, but the association was stron-
ger with the eGDR formula. A possible explanation for
these associations is that hypertension, a component of
the formula, is more prevalent in T1DM patients after
several years of the disease, although other factors were
independently associated with increased risk of hyper-
tension in T1DM as older age, male sex, family history
of hypertension, greater baseline body mass index, weight
gain, and higher albumin excretion rate [35]. Reaven first
drew attention to the association of insulin resistance,
obesity, high plasma triglycerides and low HDL choles-
terol with hypertension in the type 2 diabetes. We found
the same associations for the patients classified into the
first quartiles by both formulas for type 1 diabetics [36].
The following limitations of our study should be taken
into account. The current design was cross-sectional
and did not allow the establishment of a temporal rela-
tionship between IR, regional adiposity, and the develop-
ment of diabetes complications. The percentage of
patients who underwent DEXA was approximately 50%
of those included in the study. This occurred due to
logistical difficulties. We found no correlation between
physical activity, history of T2DM and serum levels of
LDL, unlike some authors who showed a correlation
with family history of T2DM and serum levels of LDL
[17]. However, we found an inverse correlation between
IR and lean mass, an important marker of physical activ-
ity. Physical activity plays an important role in delaying
disease progression and is inversely related to mortality
in T1DM patients [37]. The use of a simplified question-
naire concerning physical activity may have been a
source of bias. In poorly controlled diabetic patients, IRcan also result from glucotoxicity because high blood
glucose levels increases IR [10]. It is well known that
good glycaemia control reduces weight gain and possibly
decreases cardiovascular risk factors [38,39]. Our popu-
lation is characterized by miscegenation. However, when
our findings were compared to those of European popu-
lations, which are ethnically different, they did not differ.
Findings similar to our results were found in a Polish
study in which IR was evaluated by euglycaemic clamp
in 202 patients with T1DM. The authors found associa-
tions between the same variables: BMI, subscapular SF,
total insulin dose, total body fat, blood pressure, A1c,
waist size, triglycerides and age [24]. We found no asso-
ciation between other regional adiposity markers and the
values of the formulas; however, the evaluations in the
Polish study were based only on SF thickness, and no
densitometry measures were performed.
Longitudinal studies are needed to elucidate the causal
relationship between increasing adiposity and the devel-
opment of IR, CAD and nephropathy in populations
with T1DM. The determination of the role of IR in the
natural course of the disease and therapies that reduce
IR, such as changes in lifestyle, weight control, the use
of metformin [40] and control of oxidative stress, could
avoid vascular damage in these patients [41].
In summary, our data, similar those of other studies,
suggest that we can determine the presence of IR among
type 1 diabetic patients by using clinical and laboratory el-
ements because performing hyperinsulinemic-euglycemic
clamp is impractical in population studies. In our analysis,
data regarding total and regional body fat improved the
estimation of IS. As stated by other authors, the analysis
of IR risk factors is important for the overall trend of
searching for a simple method that could be used in
population studies and clinical practice [42].
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